1. First proposed panels on acute leukemia for four-color immunophenotyping by flow cytometry from the Brazilian group of flow cytometry-GBCFLUX.
- Author
-
Ikoma MR, Sandes AF, Thiago LS, Cavalcanti Júnior GB, Lorand-Metze IG, Costa ES, Pimenta G, Santos-Silva MC, Bacal NS, Yamamoto M, and Souto EX
- Subjects
- Antibodies chemistry, Antigens, CD genetics, Antigens, CD immunology, Biomarkers, Tumor genetics, Brazil, Color, Cytogenetic Analysis, Flow Cytometry methods, Fluorescent Dyes, Humans, Immunophenotyping methods, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute immunology, Leukemia, Myeloid, Acute pathology, Lymphocytes classification, Lymphocytes pathology, Myeloid Cells classification, Myeloid Cells pathology, Practice Guidelines as Topic, Precursor Cell Lymphoblastic Leukemia-Lymphoma genetics, Precursor Cell Lymphoblastic Leukemia-Lymphoma immunology, Precursor Cell Lymphoblastic Leukemia-Lymphoma pathology, Biomarkers, Tumor immunology, Flow Cytometry standards, Immunophenotyping standards, Leukemia, Myeloid, Acute diagnosis, Lymphocytes immunology, Myeloid Cells immunology, Precursor Cell Lymphoblastic Leukemia-Lymphoma diagnosis
- Abstract
Multiparameter flow cytometry is a highly sensitive, fast, and specific diagnostic technology with a wide range of applicability in hematology. Although well-established eight-color immunophenotyping panels are already available, most Brazilian clinical laboratories are equipped with four-color flow cytometer facilities. Based on this fact, the Brazilian Group of Flow Cytometry (Grupo Brasileiro de Citometria de Fluxo, GBCFLUX) for standardization of clinical flow cytometry has proposed an antibody panel designed to allow precise diagnosis and characterization of acute leukemia (AL) within resource-restricted areas. Morphological analysis of bone marrow smears, together with the screening panel, is mandatory for the primary identification of AL. The disease-oriented panels proposed here are divided into three levels of recommendations (mandatory, recommendable, and optional) in order to provide an accurate final diagnosis, as well as allow some degree of flexibility based on available local resources and patient-specific needs. The proposed panels will be subsequently validated in an interlaboratory study to evaluate its effectiveness on the diagnosis and classification of AL. (Assoc editor comm. 2)., (© 2015 International Clinical Cytometry Society.)
- Published
- 2015
- Full Text
- View/download PDF